Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2014 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.97M$1.97Mderived+57.8% vs Q4 2013 Net Income$230.68K$230.68Kderived−41.2% vs Q4 2013 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$995,656+6.4% Operating Incomederived$230,580N/M Operating Cash Flowderived$272,772−67.1% Free Cash Flowderived$268,482−67.6% Margins · derivedGross margin50.6%−24.5 pt vs Q4 2013
Operating margin11.7%+58.2 pt vs Q4 2013
Net margin11.7%−19.8 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 31, 2015 · 90 d after period end